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1946REPLY: Going Over LEGACY With a
Pinch of SaltWe thank Dr. Valentova and colleagues for high-
lighting some of the key ﬁndings of the LEGACY
(Long-term Effect of Goal-directed weight manage-
ment in an Atrial ﬁbrillation Cohort studY). This
study demonstrates that in overweight and obese
individuals with symptomatic atrial ﬁbrillation (AF),
weight loss had a dose-dependent effect on the long-
term freedom from AF (1). This was an observational
registry in which measurement and sampling bias was
minimized through standardized processes, evalua-
tion by blinded operators, and the routine collection
of outcome data. Details of patient ﬂow and attrition
are provided in the manuscript.
Controversy does exist regarding long-term sus-
tainability of weight loss. Indeed, greater weight loss
corresponded with higher participation in the weight
management clinic. In addition, the weight loss ach-
ieved in patients attending the dedicated clinic was
progressive and sustained with less ﬂuctuation. It is
incorrect to suggest that the results of this study are
an epiphenomenon due to higher compliance.
Improved lipid proﬁle, blood pressure, and glycemic
control were evident with weight loss, with the use of
fewer medications. In this series we did not have
consistent data on follow-up polysomnography;
however, in a smaller series we have presented that
weight loss reduced sleep apnea (2).
The numbers and type of antiarrhythmic drugs
used were not different at baseline. At ﬁnal follow-up
the number of antiarrhythmic drugs used was
signiﬁcantly lower with increasing weight loss. No
patient remained on amiodarone. The numbers of
ablation procedures performed in 3 groups were not
different. There were no deaths in this study.
It has been suggested that propensity score
matching (PSM) be used to mitigate potential biases
to maintain a balanced design. The baseline charac-
teristics of this cohort demonstrated no differences in
means, proportions, and distributions between the
3 weight loss groups. Thus, using PSM would not
have resulted in a signiﬁcantly higher balance to that
which is already observed. The most important
reservation in using PSM in the current analysis is the
sample size. PSM is a large sample tool and its use in
the current dataset may in fact increase the unbal-
ance among the covariates. This loss was considered
unwise given the potential nonsigniﬁcant improve-
ment in the balance between the groups.
Finally, we agree on the need for a randomized
control multicenter trial—which is underway. How-
ever, it is important to realize that the impact ofweight ﬂuctuation on AF burden cannot be evaluated
in a randomized study design. While we can argue on
the mechanisms and vacillate, given the expanding
epidemic of obesity and AF, it is prudent that primary
and secondary prevention strategies be instigated
urgently. Evidently, aggressive risk factor manage-
ment with weight loss and increased physical activity
are crucial elements in the management of AF (2,3).Rajeev K. Pathak, MBBS
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RegurgitationIn their review of secondary mitral regurgitation (MR),
Asgar et al. (1) attribute abnormal leaﬂet tethering
largely to apical and lateral papillary muscle displace-
ment. To our knowledge the ﬁrst comprehensive
quantitative echocardiographic study of this topic was
reported in 1983 (2). In that study no difference was
found in chordal eccentricity, papillary muscle teth-
ering length, and left ventricular volume between MR
and no-MR groups. Instead, the abnormal, apically
displaced tethering associatedwithMR derived almost
exclusively from annular dilation, in association with
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1947left atrial dilation. Indeed, if one performs a thought
experiment where the subvalvular apparatus is held
ﬁxed, but the annulus dilates, apical displacement of
the leaﬂets at systolic closure would be expected.
Another instance pointing to the potential role for
annular dilation is so-called atrial functional MR,
which may occur in the presence of persistent atrial
ﬁbrillation but in the absence of left ventricular
remodeling. On the other hand, papillary muscle dis-
placement may be particularly important in ischemic
disease (3). In an individual patient, both mechanisms
may contribute, and this may have practical signiﬁ-
cance. For instance, the MitraClip (Abbott Vascular,
Santa Clara, California) is the percutaneous equivalent
of the Alﬁeri edge-to-edge stitch, the latter of which
appears to more successfully treat secondary MR in
association with an undersized annuloplasty (4). It has
therefore been proposed that a percutaneous annulo-
plastymethod be used as an adjunct with theMitraClip
(5), if and when the former becomes available.*Chester M. Boltwood, Jr., MD
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Cardiothorac Surg 2011;39:807–8.REPLY: Secondary Mitral RegurgitationDrs. Boltwood and Shah focus on annular dilation as
the mechanism of apical tethering of the mitral valve
leaﬂets rather than papillary muscle displacement in
secondary mitral regurgitation (MR). In fact, annular
dilation has long been recognized as a cause of sec-
ondary MR in those with atrial ﬁbrillation and left
atrial dilation in the absence of left ventricular
dysfunction (Carpentier Type I) (1). In the setting ofleft ventricular dysfunction, however, it is generally
agreed that the major mechanism of MR in most cases
is systolic mitral valvular tenting as described by Yiu
et al. (2), due to both apical and posterior displacement
of the papillary muscles. Annular dilation is a sec-
ondary event that adds to MR severity. Although sur-
gical annuloplasty with an undersized complete rigid
ring initially completely corrects MR, MR may recur in
one-third of cases within 1 year due to ongoing left
ventricular remodeling with increased leaﬂet teth-
ering (3). Isolated treatment of annular dilation may
also fail to correct severe anterior leaﬂet tethering in
the case of apical displacement of the papillary mus-
cles (4). Finally, the MitraClip (Abbott Vascular, Santa
Clara, California) has proven to durably reduce MR in
both primary and secondary MR, even without an
annuloplasty (5). The mechanism in part is likely due
to stabilizing the septal lateral dimension of the mitral
annulus, similar to surgical annuloplasty. Further
study is required to determine whether transcatheter
annuloplasty offers equivalent long-term effective-
ness as the MitraClip for secondary MR, and whether
the combination of annuloplasty plus the MitraClip
provides incremental beneﬁt. If it does, it will most
likely be in those patients with the greatest degree of
annular dilation and leaﬂet tethering.Anita W. Asgar, MD
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